Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX   US92532F1003

Delayed Quote. Delayed Nasdaq - 09/02 12:27:30 pm
92.59 USD   -1.05%
5d ago VERTEX PHARMACEUTICALS : Saskatchewan to cover expensive cystic fibrosis dr..
5d ago NASDAQ 100 MOVERS : Vip, vrtx
08/22 VERTEX PHARMACEUTICALS : Assigned Patent
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vertex Pharmaceuticals Inc
Discovers and develops novel, small molecule pharmaceuticals

Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs.

The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation.

The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787.

Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.
Managers
NameAgeSinceTitle
Matthew W. Emmens622004Director
Joshua S. Boger, PhD621989Director
Bruce I. Sachs, MBA541998Co-Lead Independent Director
Elaine S. Ullian661997Co-Lead Independent Director
Peter R. Mueller, PhD572003Chief Scientific Officer
Ian F. Smith482001Chief Financial Officer & Executive Vice President
Michael Partridge--Vice President-Investor Relations
Amit K. Sachdev462007SVP-Global Government Strategy & Market Access
Lisa Kelly-Croswell-2006Senior Vice President-Human Resources
Valerie Lynne Andrews542002Vice President & General Counsel
Shareholders
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
ASTRAZENECA PLC
ABBVIE INC
BIOGEN IDEC INC
CELGENE CORPORATI..
ALEXION PHARMACEU..
VERTEX PHARMACEUT..
UCB
GRIFOLS SA
JAZZ PHARMACEUTIC..
CUBIST PHARMACEUT..
CHONGQING ZHIFEI ..
-
THERAVANCE INC
BEIJING TIANTAN B..
-
WALVAX BIOTECHNOL..
-
ABCAM PLC
CELLDEX THERAPEUT..
GREEN CROSS CORP
ARIAD PHARMACEUTI..
Sector Pharmaceuticals
Company contact information
50 avenue Northern
US-MA 02110 Boston, Massachusetts
USA

Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 / SP500
Stock Exchange Codes
- ISIN Code :  US92532F1003
- Bloomberg Code :  VRTX:US
- Reuters Code :  VRTX.O
- Datastream Code :  
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF